Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2019	Apr. 24, 2020	Jun. 30, 2019
Cover page.
Document Type	10-K/A
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	333-199861
Entity Registrant Name	MYLAN N.V.
Entity Incorporation, State or Country Code	P7
Entity Tax Identification Number	98-1493528
Entity Address, Address Line One	Building 4
Entity Address, Address Line Two	Trident Place
Entity Address, Address Line Three	Mosquito Way
Entity Address, City or Town	Hatfield
Entity Address, Postal Zip Code	AL10 9UL
Entity Address, Country	GB
Country Region	44
City Area Code	1707
Local Phone Number	853-000
Title of 12(b) Security	Ordinary shares, nominal value €0.01
Trading Symbol	MYL
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Common Stock, Par or Stated Value Per Share	$ 0.01
Entity Public Float			$ 12,814,190,996
Entity Common Stock, Shares Outstanding		516,944,470
Entity Central Index Key	0001623613
Amendment Flag	true
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Amendment Description	This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, originally filed on February 28, 2020 (the “Original Filing”). We are filing this Amendment to include the information required by Part III and not included in the Original Filing, as we do not intend to file a definitive proxy statement for an annual general meeting of shareholders within 120 days of the end of our fiscal year ended December 31, 2019. In addition, in connection with the filing of this Amendment and pursuant to the rules of the Securities and Exchange Commission (the “SEC”), we are including with this Amendment new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new certifications. Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing. As used in this Amendment, unless the context requires otherwise, the “Company,” “Mylan,” “our,” and “we” mean Mylan N.V. and its consolidated subsidiaries, “NASDAQ” means The NASDAQ Global Select Stock Market, and “U.S. GAAP” means accounting principles generally accepted in the United States (“U.S.”). On July 29, 2019, Mylan, Pfizer Inc. (“Pfizer”), Upjohn Inc. (“Upjohn”), a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which the Company will combine with Pfizer’s Upjohn Business (the “Upjohn Business”) in a Reverse Morris Trust transaction (the “Combination”). Upjohn will be the parent entity of the combined Upjohn Business and Mylan business and will be renamed “Viatris” effective as of the closing of the Combination. The consummation of the Combination is subject to various customary closing conditions, including receipt of regulatory approvals and approval of the Combination by Mylan’s shareholders, and is anticipated to close in the second half of 2020.